The mechanisms by which oligodendroglia modulate CNS angiogenesis remain elusive.
Introduction
The vasculature of the central nervous system (CNS), which is developed exclusively through angiogenesis, plays a crucial role in providing neural cells with nutrients and oxygen.
CNS angiogenesis, the growth of new blood vessels from pre-existing ones, starts during embryonic development and matures during postnatal development in human and rodent brains, for example, by the age of one month in rodents 1 . Dysregulated CNS angiogenesis negatively impacts postnatal brain development and functional recovery from brain injuries [2] [3] [4] . The current study aimed to dissect the molecular regulation of postnatal CNS angiogenesis using in vivo genetic animal models.
The developing CNS parenchyma is exposed to physiological hypoxia with local oxygen concentration ranging from 0.5% to 7% 5 . Hypoxia inducible factor α (HIFα) is a critical regulator that adapts neural cells to hypoxic conditions. The transcription factor HIFα, including HIF1α and HIF2α, is subjected to constant degradation. Von Hippel-Lindau (VHL), a negative regulator of HIFα's transcriptional activity, plays an essential role in HIFα degradation. Under low oxygen or upon VHL disruption, HIF1α and HIF2α degradation is impaired and subsequently translocate into the nuclei where they regulate downstream target genes through forming transcriptional active complexes with the constitutive HIF1β 6,7 . Previous data suggest that HIFα function in neural precursor cells is required for embryonic brain vascular development 8 . Recent data including those from our own laboratory show that HIFα function in oligodendroglial lineage cells may play a pivotal role in regulating postnatal angiogenesis in the brain white matter 9 and in the spinal cord 10 . However, the molecular mechanisms underlying oligodendroglial HIFα-regulated angiogenesis are still controversial and remain incompletely defined.
The current concept stated that oligodendroglial HIFα promotes CNS angiogenesis through activating signaling pathway of Wnt but not vascular endothelial growth factor (VEGF) 9 .
However, this "Wnt-dependent" view was supported only by in vitro studies and pharmacological manipulations 9 , in which "pathological" activation of Wnt signaling, poor cell-type selectivity and/or off-target effects of small compounds cannot be excluded. In this study, we presented compelling in vivo evidence supporting an alternative view in our mechanistic understanding of oligodendroglial HIFα-regulated CNS angiogenesis. Our in vivo genetic knockout data reveal that oligodendroglial HIFα regulates endothelial cell proliferation and angiogenesis in a VEGFdependent but Wnt-independent manner and this regulation is independent of CNS regions during postnatal development. Very interestingly, our data also demonstrate that postnatal astroglia regulate CNS angiogenesis at least in part through HIFα-activated Wnt signaling, unveiling a glial cell type-specific HIFα-Wnt connection in the CNS.
Results
Endothelial cell (EC) proliferation is an essential step of angiogenesis and the blood vessel density is an end-point reflection of angiogenesis. Therefore, we used EC proliferation and vessel density as in vivo readouts of angiogenesis 9 . To quantify blood vessel density, we used the basement membrane marker Laminin to label blood vessels and employed a semiautomated approach to calculate the percentage of Laminin-occupying area among total assessed area ( Supplementary Fig. 1 ). To determine whether oligodendroglial HIFα is required for angiogenesis throughout the postnatal CNS, Cre-LoxP approach was used to genetically ablate or stabilize HIFα and EC proliferation and vessel density were analyzed in the brain and the spinal cord.
Oligodendroglia regulate CNS angiogenesis through HIFα-mediated signaling in a manner independent of CNS regions
We used Cnp-Cre line 11 to generate Cnp-Cre:Hif1α fl/fl (HIF1α conditional knockout, cKO), Cnp-Cre: Hif2α fl/fl (HIF2α cKO), and Cnp-Cre: Hif1α fl/fl :Hif2α fl/fl (HIF1α/HIF2α or HIFα double cKO) mutants ( Supplementary Fig. 2 ). Mice carrying Cnp-Cre transgene alone did not display any developmental abnormalities compared with non-Cre animals as previously reported 11 and supported by our assessment of CNS angiogenesis and motor function ( Supplementary Fig. 3 ).
HIF1α cKO or HIF2α cKO did not influence blood vessel density, indicating a compensatory effect of oligodendroglial HIF1α and HIF2α on angiogenesis. In contrast, HIF1α/HIF2α double cKO (refer to as HIFα cKO hereafter) significantly impaired CNS angiogenesis evidenced by reduced blood vessel density (Fig. 1a-c) and diminished EC proliferation not only in the cerebral cortex but also in the spinal cord ( Fig. 1d-g ), suggesting that oligodendroglial HIFα is necessary for CNS angiogenesis.
The HIFα protein is constantly translated but subjected to rapid turnover via proteasomemediated degradation, a process in which Von Hippel-Lindau product (VHL) is essential for HIFα degradation. Therefore, we employed Cnp-Cre:Vhl fl/fl transgenic mice to genetically ablate VHL and stabilize HIFα function in oligodendroglial lineage cells ( Supplementary Fig. 4 ). We found that the density of blood vessels and the proliferation of ECs were significantly increased in the cerebral cortex and spinal cord of Cnp-Cre:Vhl fl/fl mice compared with those of non-Cre control mice at different time points in the early postnatal CNS (Fig. 1h-j) . Stabilizing HIFα in oligodendroglial lineage cells did not have a major effect on the integrity of the blood brain (spinal cord) barrier in the adult Cnp-Cre:Vhl fl/fl mice ( Supplementary Fig. 5 ).
Previous studies have reported that Cnp-Cre primarily targets oligodendroglial lineage cells and also a subpopulation of early neural progenitor cells 12, 13 . To corroborate the conclusion derived from Cnp-Cre transgenic mice, we assessed CNS angiogenesis in a different animal strain Sox10-Cre:Vhl fl/fl in which Sox10-Cre mediated HIFα stabilization in the earlier stages of oligodendrocyte development in the CNS. Consistently, CNS angiogenesis was significantly increased in Sox10-Cre:Vhl fl/fl mutants, as assessed by elevated blood vessel density (Fig. 1k ), EC-specific Pecam1 mRNA expression ( Fig. 1l ), and EC densities (Fig. 3m ).
Taken together, our loss (gain)-of-function results suggest that that oligodendroglial HIFα is necessary and sufficient for angiogenesis and that the angiogenic regulation by oligodendroglial HIFα is independent of CNS regions.
Oligodendroglial HIFα does not regulates the activity of Wnt/β-catenin signaling in vivo and in vitro
To determine whether HIFα in oligodendroglial lineage cells regulates Wnt/β-catenin signaling, we quantified the Wnt/β-catenin target gene Axin2, Naked1, and Notum, which are reliable readouts for the signaling activation 10 . We found no significant changes in the mRNA levels of those genes in HIFα-stabilized spinal cord and forebrain of Cnp-Cre:Vhl fl/fl mutants at different time points ( Fig. 2a ) compared with those of non-Cre controls. Consistently, Western blot assay showed that the active form of β -catenin (dephosphorylated on Ser37 or Thr41) and
Axin2 did not change (Fig. 2b) , indicating that stabilizing oligodendroglial HIFα does not perturb the activity of Wnt/β-catenin signaling in the CNS. Furthermore, we found no significant change in the mRNA level of Wnt7a in the CNS of Cnp-Cre:Vhl fl/fl mice compared with non-Cre controls ( Fig. 2c ). We crossed Wnt reporter transgenic mice BAT-lacZ 14 with Cnp-Cre:Vhl fl/fl mutants and found no difference in lacZ mRNA level in the spinal cord of BAT-lacZ/Cnp-Cre:Vhl fl/fl mice compared with age-matched BAT-lacZ mice (Fig. 2d ).
We further assessed the activity of Wnt/β-catenin signaling in a different animal strains of Sox10-Cre:Vhl fl/fl mice. Consistent with Cnp-Cre:Vhl fl/fl mice, HIFα was stabilized in the CNS of Sox10-Cre:Vhl fl/fl mutants, as shown by the elevated expression of HIFα target gene Hk2 ( Fig.   2e ). However, Wnt/β-catenin signaling was not perturbed, as evidenced by similar activity of Wnt/β-catenin signaling assessed at the mRNA ( Fig. 2f ) and protein ( Supplementary Fig. 6 ) levels. The unperturbed activity of Wnt/β-catenin signaling was further corroborated by evidences from a time-conditional Pdgfrα-CreER T2 :Vhl fl/fl strain in which Pdgfrα-CreER T2 elicited a greater than 85% of recombination efficiency and specificity in early postnatal oligodendrocyte progenitor cells (OPCs) ( Supplementary Fig. 7 ). Tamoxifen-induced VHL ablation in OPCs resulted in HIFα stabilization and elevated angiogenesis, as demonstrated by significant increase in the expression of HIFα target gene Hk2 and EC-specific Pecam1 (Fig. 2g ) and the density of cerebral blood vessels ( Fig. 2h ). However, the mRNA expression of Wnt target genes Ainx2 and Sp5 (Fig. 2i ) and the protein levels of active β -catenin and Naked1 (Supplementary Previous study reported an autocrine activation of Wnt/β-catenin signaling in OPCs by HIFα stabilization 9 . To assess the autocrine activity of Wnt/β-catenin signaling, we treated purified primary OPCs with HIFα stabilizer DMOG 9 in the present or absence of HIFα signaling blocker Chetomin 15 ( Supplementary Fig. 9a ). Our results showed that pharmacological stabilizing HIFα activated HIFα signaling target genes ( Supplementary Fig. 9b ) but did not activate Wnt/β-catenin target genes nor Wnt7a and Wnt7b ( Supplementary Fig. 9c ) in primary OPCs isolated from neonatal brain. We also quantified the activity of Wnt/β-catenin signaling in primary OPCs which were isolated from neonatal Sox10-Cre:Vhl fl/fl brain. Consistent with the in vivo data ( Fig. 2e ), HIFα target genes were significantly increased in primary VHL-deficient OPCs (Fig. 2j ). However, neither Wnt/β-catenin target genes Axin2 and Naked1 nor Wnt7a were increased in primary VHL-deficient OPCs ( Fig. 2k ), suggesting that stabilizing oligodendroglial HIFα does not perturb Wnt/β-catenin signaling in primary OPCs.
To determine whether HIFα deletion affects Wnt/β-catenin signaling, we analyzed Wnt/βcatenin activity in the early postnatal CNS of Cnp-Cre:HIFα cKO and Pdgfrα-CreER T2 :HIFα cKO mutants. Consistent with HIFα-stabilized mutants (Fig. 2) , we found no evidence of Wnt/βcatenin signaling perturbation in both strains of HIFα cKO mutants ( Supplementary Fig. 10 ).
Collectively, our in vivo and in vitro data demonstrate that Wnt/β-catenin signaling is unlikely a downstream target of oligodendroglial HIFα as previously reported 9 and suggest that oligodendroglial HIFα may regulate CNS angiogenesis independent of Wnt/β-catenin signaling.
Blocking oligodendroglia-derived Wnt signaling does not affect HIFα-regulated

CNS angiogenesis
WLS is an essential factor of Wnt secretion from Wnt-producing cells and its deficiency blocks Wnt ligands from activating the downstream pathways in Wnt-receiving cells [16] [17] [18] [19] . To determine whether WLS deficiency affects Wnt secretion from oligodendroglial lineage cells, we knocked down WLS in primary Wnt7a-expressing OPCs and assessed Wnt secretion and autocrine Wnt/β-catenin activity (Fig. 3a, b ). We expressed Wnt7a given that Wnt7a is reported as one of the Wnt ligand genes expressed in OPCs at the mRNA level 9,20 . Our enzyme-linked immunosorbent assay (ELISA) of the culture medium showed that WLS knockdown significantly reduced Wnt7a concentration secreted from Wnt7a-expressing OPCs (Fig. 3c ). Autocrine Wnt/β-catenin signaling was activated in Wnt7a-expressing OPCs, as evidenced by the increased expression of Wnt target genes Axin2 and Sp5 (Fig. 3d ), but this activation was blocked in WLS-deficient OPCs (Fig. 3d ). Our data suggest that WLS is required for Wnt secretion from OPCs.
To define the putative in vivo role of Wnt signaling in HIFα-regulated CNS angiogenesis, we generated VHL/WLS double mutant hybrids to block Wnt secretion from HIFα-stabilized oligodendroglial lineage cells ( Fig. 4a ). Because constitutive Sox10-Cre:Vhl fl/fl pups died at very early postnatal ages, we used an inducible Cre line Sox10-CreER T2 to stabilize HIFα and disrupt WLS in Sox10 + oligodendroglial lineage cells (OPCs and differentiated oligodendroglia). Our fate-mapping data showed that Sox10-CreER T2 elicited ~60% of recombination efficiency and greater than 90% of oligodendroglial specificity in Sox10 + oligodendroglial lineage cells in the early postnatal CNS ( Supplementary Fig. 11 ). We confirmed that HIFα's function was indeed stabilized in the spinal cord of Sox10-CreER T2 :Vhl fl/fl (HIFαstabilized mice) and Sox10-CreER T2 :Vhl fl/fl :Wls fl/fl ( HIFα-stabilized/WLS-disrupted mice), as evidenced by the elevated expression of HIFα target gene Hk2 (Fig. 4d ) and Ldha (Fig. 4e ) in comparison with non-Cre controls. Our analysis demonstrated that blocking Wnt secretion by disrupting WLS did not alter HIFα stabilization-elicited CNS angiogenesis in HIFαstabilized/WLS-disrupted mice compared with HIFα-stabilized mice, which was supported by unchanged levels of endothelial Pecam1 mRNA expression ( Fig. 4f ) and unchanged densities of blood vessels ( Fig. 4g -j), ERG + ECs (Fig. 4k ), and ERG + EdU + dividing ECs (Fig. 4l ) in the spinal cord and cerebral cortex of HIFα-stabilized/WLS-disrupted mice compared with those of HIFαstabilized mice. These data suggest that oligodendroglial lineage-derived Wnt signaling plays a minor role in HIFα-regulated angiogenesis in the early postnatal CNS.
Next, we used a different Cre transgenic line Pdgfrα-CreER T2 to stabilize HIFα specifically in OPCs. OPC-specific HIFα stabilization enhanced blood vessel density ( Fig. 5a-d) and increased the number of ERG + ECs ( Fig. 5e-f ) in the spinal cord and cerebral cortex of Pdgfrα-CreER T2 :Vhl fl/fl animals compared with those in non-Cre controls. However, blocking Wnt secretion from OPCs by disrupting WLS did not affect blood vessel formation and endothelial cell density in the CNS of HIFα stabilized/WLS-disrupted mice compared with HIFα stabilized mice (Pdgfrα-CreER T2 :Vhl fl/fl :Wls fl/fl versus Pdgfrα-CreER T2 :Vhl fl/fl ) ( Fig. 5c-f ). The data from two independent Cre transgenic lines collectively suggest that oligodendroglia-derived Wnt signaling is dispensable for HIFα-regulated CNS angiogenesis in vivo.
VEGFA expression is upregulated in the CNS of oligodendroglial HIFα-stabilized transgenic mice
A previous study reported that VEGFA was unperturbed by oligodendroglial HIFα stabilization 9 . We revisited the potential connection between HIFα and VEGFA in oligodendrocytes both in vivo and in vitro. HIF1α cKO (or HIF2α cKO) alone did not alter Vegfa (Fig. 6h ). Furthermore, Vegfa mRNA was elevated by greater than 3-fold in primary OPCs purified from neonatal Sox10-Cre:Vhl fl/fl mice compared with those from non-Cre littermate controls ( Fig. 6i ). All these data suggest that VEGFA is regulated by HIFα in oligodendroglial lineage cells.
Blocking oligodendroglia-derived VEGFA significantly reduces oligodendroglial
HIFα-regulated CNS angiogenesis
The regulation of VEGFA by oligodendroglial HIFα led us to hypothesize that VEGFA may be a crucial downstream molecule that couples oligodendroglial HIFα and CNS endothelial cell proliferation and vessel formation. To test this hypothesis, we generated Pdgfrα-CreER T2 :Vhl fl/fl :Vegfa fl/fl (HIFα-stabilized/VEGFA-disrupted), Pdgfrα-CreER T2 :Vhl fl/fl (HIFαstabilized), and non-Cre control mice ( Fig. 7a, b ). The mRNA level of EC-specific marker PECAM1 was significantly attenuated in the spinal cord of Pdgfrα-CreER T2 :Vhl fl/fl : Vegfa fl/fl mice compared with that of Pdgfrα-CreER T2 :Vhl fl/fl mice (Fig. 7c ). The densities of blood vessels ( Fig.   7d -e), ERG + total ECs (Fig. 7f ), and ERG + BrdU + proliferating ECs ( 
Blocking Wnt secretion from astroglia attenuates astroglial HIFα-regulated CNS angiogenesis
Astroglial maturation is also temporally and functionally coupled with postnatal CNS angiogenesis. We assess the connection of astroglial HIFα and Wnt/β-catenin activation in the CNS. We first used the mouse Gfap promoter-driven constitutive Cre, i.e. mGfap-Cre to genetically stabilize HIFα in astroglia. The efficiency of mGfap-Cre-mediated recombination among astroglial lineage cells, quantified by Cre-mediated EYFP reporter, was low (~35%) in the CNS in the early postnatal CNS by P10 ( Supplementary Fig. 12a -c) and progressively increased during postnatal CNS development (supplementary Fig. 12d-f ). Our fate-mapping data showed that EYFP reporter, which is an indicator of mGfap-Cre activity, was expressed in GFAP + or S100β + astrocytes, but not in Sox10 + oligodendroglial lineage cells, NeuN + neurons ( Fig. 8a ), or ERG + ECs (data not shown) in the spinal cord and the cerebral cortex of adult mGfap-Cre:Rosa26-EYFP mice at P60, confirming that mGfap-Cre primarily targets astroglial lineage cells in those CNS regions.
We observed a significant increase in the density of Laminin + blood vessels (Fig. 8b, c) and in the mRNA expression of EC-specific PECAM1 (Fig. 8d ) throughout the CNS of mGfap-Cre:Vhl fl/fl mutants compared with non-Cre control mice by P30 when Cre-mediated recombination efficiency was greater than 80% ( Fig. 8a , Supplementary Fig. 12 ). Double immunohistochemistry showed that blood-borne macromolecule IgG was confined to Laminin + blood vessels in mGfap-Cre:Vhl fl/fl mice, a similar pattern to that in age-matched non-Cre controls ( Fig. 8e, arrowheads) , indicating that the function of the blood brain (spinal cord) barrier does not appear compromised although the vessel density is elevated.
Unexpectedly, we found that stabilizing HIFα in astroglial lineage cells ( Fig. 8f) remarkably activated Wnt/β-catenin signaling in the CNS of mGfap-Cre:Vhl fl/fl mice, as shown by significant elevation in the expression of Wnt/β-catenin signaling target genes Axin2 and Notum in spinal cord and brain ( Fig. 8g ). Histological ( Fig. 8h ) and Western blot (cf Fig. 9a Our results indicated that the constitutive mGfap-Cre elicited a poor recombination efficiency in early postnatal astrocytes ( Supplementary Fig. 12 ). To determine whether early postnatal astrocytes regulate CNS angiogenesis through HIFα-activated Wnt signaling, we generated Aldh1l1-CreER T2 :Vhl fl/fl :Wls fl/fl mutants. Our data demonstrated a greater than 90% of recombination efficiency and 95% of astroglial specificity in the spinal cord and cerebral cortex of Aldh1l1-CreER T2 :Rosa26-EYFP at P8 when tamoxifen was injected at P1, P2, and P3 ( Supplementary Fig. 13 ). Consistent with the data derived from mGfap-Cre:Vhl fl/fl :Wls fl/fl strain, we found that the densities of blood vessels and ECs were significantly increased in Aldh1l1-CreER T2 :Vhl fl/fl mutants compared with those in non-Cre controls and that simultaneous WLS ablation significantly reduced the densities of blood vessels and ECs in the cortex and spinal 1 0 cord of Aldh1l1-CreER T2 :Vhl fl/fl :Wls fl/fl mutants compared with those of Aldh1l1-CreER T2 :Vhl fl/fl animals at early postnatal age of P8 ( Fig. 10) . These data provide a strong genetic proof that HIFα-activated Wnt signaling is a major downstream pathway by which astroglia regulate angiogenesis during postnatal CNS development.
Discussion
The maturation of glial cells including oligodendroglia and astroglia in the developing human and murine brain is temporally and functionally coupled with the maturation of the CNS vascular network 21 . The regulation of CNS angiogenesis by glial cells is critical for postnatal CNS development and investigating the molecular underpinnings of CNS angiogenesis has clinical implications in neural repair after CNS damage in which hypoxia is commonly present 4, 21, 22 . In this study, we employed a battery of genetic mutant mice and presented several significant and novel findings: 1) oligodendroglial HIFα is necessary and sufficient for postnatal CNS angiogenesis and this regulation occurs in a manner independent of CNS regions; 2) In sharp contrast to previous report 9 , HIFα stabilization in oligodendroglial lineage cells does not perturb Wnt/β-catenin signaling, but remarkably activates VEGF, and genetically blocking oligodendroglia-derived VEGF but not Wnt reduces oligodendroglial HIFα-regulated CNS angiogenesis; 3) Wnt signaling is a downstream pathway by which astroglial HIFα regulates CNS angiogenesis. Our findings represent an alternative view in our mechanistic understanding of oligodendroglial HIFα-regulated angiogenesis from a Wnt-dependent/VEGF-independent view 9 to a VEGF-dependent/Wnt-independent one, and also unveil a glial cell type-dependent HIFα-Wnt axis (oligodendroglial vs astroglia) in regulating CNS angiogenesis ( Supplementary   Fig. 14) .
Previous data suggest that the regulation of Wnt/β-catenin signaling (activation or repression) by HIFα is cell type and/or context-dependent 10,23-27 . It is important to determine whether HIFα in CNS glial cells differentially regulates Wnt/β-catenin signaling in vivo. A recent study reported that oligodendroglial HIFα could activate Wnt/β-catenin signaling not only in oligodendroglial lineage cells but also in endothelial cells through HIFα-mediated Wnt7a/7b expression 9 . However, the in vivo and in vitro data presented in this study do not support this assertion. In our study, we employed five different strains of oligodendroglial Cre (two constitutive Cre and three inducible Cre) to genetically stabilize HIFα and found no evidence of Wnt/β-catenin activation or Wnt7a/7b upregulation in the brain and the spinal cord and in primary OPCs. The failure to detect Wnt/β-catenin activation is unlikely due to the inefficiency of HIFα stabilization because the canonical HIFα target genes, for example, those which are involved in glycolysis, are consistently and significantly upregulated in our transgenic animals and in primary OPCs, thus verifying the efficacy of HIFα stabilization. In sharp contrast, we found that Wnt/β-catenin signaling activity is significantly upregulated in the CNS of astroglial HIFα-stabilized mice, suggesting that our experimental approach is effective in quantifying the changes of Wnt/β-catenin activity and that the regulation of Wnt/β-catenin signaling by HIFα is glial cell type-dependent in the CNS.
Inspired by glial cell type (oligodendroglia vs astroglia)-dependent activation of Wnt/βcatenin signaling, we proposed a working model in which HIFα-activated Wnt signaling regulates endothelial cell proliferation and vessel formation in a cell type-dependent manner ( Supplementary Fig. 14) . To avoid the intrinsic caveats of pharmacological compounds and in vitro culture systems, we employed in vivo genetic models of VHL/WLS double cKO to stabilize HIFα and simultaneously disrupt the secretion of Wnt ligands. Indeed, our data demonstrate that WLS-deficiency decreases Wnt secretion and Wnt7a-induced autocrine Wnt/β-catenin signaling in primary OPCs and that disrupting WLS in astroglia reduces the activity of astroglial HIFα-regulated Wnt/β-catenin signaling in the CNS. Based on VHL/WLS double cKO systems, we provide strong genetic evidences that HIFα-regulated Wnt signaling from astroglia but not oligodendroglia plays a crucial role in regulating postnatal CNS angiogenesis. Our findings argue against a major role oligodendroglia-derived/HIFα-activated Wnt/β-catenin signaling in angiogenesis in the developing murine CNS as previously reported 9 .
There are 19 Wnt ligands in rodents, which can be grossly classified into canonical and non-canonical sub-types depending on the necessity of β -catenin for the signaling activation 10 .
WLS ablation blocks the secretion of all Wnt members from Wnt-producing cells [16] [17] [18] [19] 28 . In our genetic models, we demonstrate that ablation of WLS remarkably reduces astroglial HIFαmediated canonical Wnt/β-catenin signaling. However, we cannot exclude the possibility that astroglia-derived non-canonical Wnt signaling is also altered in our genetic manipulation which may be potentially involved in CNS angiogenenic regulation 29 . Moreover, it remains unclear which Wnt ligand(s) plays a major role in coupling astroglial HIFα with CNS angiogenesis. Our preliminary data do not support a major role of Wnt7a/7b, because neither Wnt7a nor Wnt7b expression was activated in oligodendroglial and astroglial HIFα-stabilized CNS. Future studies are needed to pinpoint which Wnt ligand(s) are the downstream mediator(s) of astroglial HIFαregulated CNS angiogenesis. VEGF (i.e. VEGFA) is a well-established angiogenic and neurotrophic factor in the CNS 4,30-35 . VEGFA regulates angiogenesis in the developing and adult CNS through its membrane-bound receptors VEGFR-1(Flt1) and VEGFR-2 (Kdr) 30 . In the early postnatal CNS, VEGFR-1 and 2 are highly expressed in the vascular ECs. However, the ligand VEGFA is barely detectable in the vascular ECs but highly expressed in the parenchymal neural cells including oligodendroglial lineage cells 20, [36] [37] [38] . Previous study suggested that the HIFα-VEGF connection did not occur in the CNS oligodendroglia 9 although this connection was demonstrated in the retina 39 . In this study, we found that oligodendroglial HIFα cKO reduces VEGFA whereas oligodendroglial HIFα stabilization increases VEGFA expression, indicating that HIFα transcriptionally regulates VEGFA in oligodendroglial lineage cells. Further corroborating these findings, purified primary OPCs respond to HIFα signaling stabilizer (DMOG) and blocker (Chetomin) by activating and inactivating VEGFA, respectively. Our results are consistent with previous data showing that VEGFA is a direct transcriptional target of HIFα 40-42 .
By leveraging our unique in vivo genetic models of VHL/VEGFA double cKO, we unequivocally prove that VEGFA is an essential downstream molecule that couples oligodendroglial HIFα function and vascular angiogenesis in the CNS, which is different from Yuen et al., 9 who reported that VEGFA was unchanged in the CNS of oligodendroglial HIFα-stabilized mutants.
The discrepancy may presumably reflect the intrinsic differences of in vitro pharmacological interventions and in vivo genetic manipulations.
It has been suggested that Wnt signaling regulates VEGF, or vice versa, to control angiogenesis [43] [44] [45] . It is possible that Wnt/β-catenin signaling is required for, or synergistically regulates, HIFα-activated VEGFA expression. Our data do not support this possibility. First, stabilizing oligodendroglial HIFα activates VEGFA but not Wnt/β-catenin signaling. Second, VEGF expression is indistinguishable in the CNS of oligodendroglial VHL/WLS double cKO mutants from that of oligodendroglial VHL single cKO mutants (data not shown), indicating that oligodendroglial-derived Wnt signaling plays a minor role in VEGFA expression. Third, Wnt/βcatenin activity is comparable in the CNS of oligodendroglial VHL/VEGFA double cKO mutants and VHL single cKO mutants, implying that oligodendroglia-derived VEGFA has no regulatory role in Wnt/β-catenin activity. Together, our results does not support a major interplay between oligodendroglial HIFα-activated VEGFA and Wnt/β-catenin signaling in modulating CNS angiogenesis.
Previous studies including those from our own laboratory 10,12,46-49 have shown that dysregulated Wnt/β-catenin activity invariably inhibits oligodendrocyte differentiation and myelination. Given the normal level of Wnt/β-catenin activity in the CNS of oligodendroglial HIFα-stabilized mutants, our study will spark renewed interests in studying Wnt-independent mechanisms underlying the impairment of oligodendroglial differentiation and myelination in HIFα-stabilized mutants as previously reported 9 . Interestingly, HIFα is stabilized and enriched in oligodendroglia in the active demyelinating lesions and normal appearing white matter (NAWM) of multiple sclerosis patient brains [50] [51] [52] [53] . We show that HIFα stabilization in oligodendrocytes remarkably activates the angiogenic and neurotrophic factor VEGF in the CNS. The genetic models generated in our study also provide a powerful tool in determining the role of HIFα stabilization in OPCs and oligodendrocytes in the pathophysiology of demyelination and remyelination in multiple sclerosis and other neurological disorders in which hypoxia-like tissue injury occurs. Rosa26-EYFP (RRID: IMSR_JAX:006148). Animals were housed at 12h light/dark cycle with free access to food and drink, and both males and females were used in this study. The single transgenic mice were crossed to generate double or triple transgenic mice indicated in the study.
Methods
Animals
All Cre transgene was maintained as heterozygous. All transgenic mice were maintained on a C57BL/6 background. Animal protocols were approved by Institutional Animal Care and Use Committee at the University of California, Davis.
Primers used for genotyping Hif1α-floxed, Hif2α-floxed and Vhl-floxed and for detecting Cre-mediated DNA deletion (as in Fig. 1A and Fig. 2A-B ) were derived from previous study 55 and listed here. Hif1α-F1: 5′-TTGGGGATGAAAACATCTGC-3′, Hif1α-F2: 5′- 
Primary OPC culture
Primary mixed glial culture (MG) was prepared from the forebrains of neonatal pups between ages P0 and P2. The isolated cortical tissues were dissociated by papain dissociation kit (#LK003176, Worthington) supplemented with DNase I (250U/ml; #D5025, Sigma) and D-(+)glucose (0.36%; #0188 AMRESCO) in 33 ºC/10% CO 2 for 90 min. Next, the tissues were transferred in PDS Kit-Inhibitor solution (#LK003182, Worthington). Tissue chunks were triturated, and then collect the cell suspension supernatant. After centrifugation, cells were plated on poly-D-lysine (PDL, #A003-E, Millipore)-coated 10 cm dishes (#130182, Thermo Scientific) in high glucose DMEM medium (#1196092, Thermo Fisher) with 10% heatinactivated fetal bovine serum (#12306-C, Sigma) and penicillin/streptomycin (P/S, #15140122, Thermo Fisher). After 24h, attached cells were washed with HBSS (#24020117, Thermo Fisher) to remove serum, and maintained with serum free growth medium (GM), a 3:7 mixture (v/v) of B104 neuroblastoma-conditioned medium, 10 ng/ml Biotin (#B4639, Sigma), and N1 medium (high glucose DMEM supplemented with 5 μg/ml insulin (#I6634, Sigma), 50 μg/ml apotransferrin (#T2036, Sigma), 100 μM Putrescine (#P5780, Sigma) 30 nM Sodium selenite (#S5261, Sigma), 20 nM Progesterone (#P0130, Sigma). We performed immunopanning 96 h after GM maintenance. Before immunopanning, cells were resuspended in panning solution (0.1% BSA in N1 medium). The cells were panned once with the anti-Thy1.2 antibody (#105302, Biolegend) for negative immunopanning and then panned once with the anti-NG2 antibody (#AB5320, Millipore) for positive immunopanning. OPCs were cultured on PDL-coated plates with complete GM. The complete GM consisted of GM with 5 ng/ml FGF(#450-33, Peprotech), 4 ng/ml PDGF-AA (#315-17, Peprotech), 50 µM Forskolin (#6652995, Peprotech,) and glutamax (#35050, Thermo Fisher). To induce differentiation, the medium was switched to differentiation medium (DM), which consists of 12.5 μg/ml insulin, 100 μM Putrescine, 24 nM Sodium selenite, 10 nM Progesterone, 10 ng/ml Biotin, 50 μg/ml Transferrin (#T8158, Sigma), 30 ng/ml 3,3',5-Triiodo-L-thyronine (#T5516, Sigma), 40 ng/ml L-Thyroxine (#T0397, Sigma-Aldrich), glutamax and P/S in F12/high-glucose DMEM, 1:1 in medium (#11330032, Thermo Fisher Scientific).
HIFα signaling stabilization and blockade in vitro by pharmacological approaches
Purified brain primary OPCs were pre-incubated with 100nM Chetomin or DMSO control for 2h, and then switched to the fresh culture medium with 1mM Dimethyloxalylglycine (DMOG, D3695, Sigma) in the presence of 100nM Chetomin (C9623, Sigma) or DMSO (D8418, Sigma) control for 7 hours before RNA preparation. 
VEGFA ELISA assay of primary OPCs
Tissue processing, immunohistochemistry, and semi-automated quantification of blood vessel density
Study mice were perfused with ice-cold phosphate buffer saline (PBS, PH7.0, Catalog #BP399-20, Fisher Chemical), and then post-fix in fresh 4% paraformaldehyde (PFA, Catalog #1570-S, Electron Microscopy Science ,PA) at room temperature(RT) for 2 hours. The CNS tissue was washed in ice-cold PBS for three times, 15 minutes each time. The samples were cryoprotected with 30% sucrose in PBS (Sucrose, Catalog #S5-3, Fisher Chemical) for 20 hours followed by sectioning. Sixteen micron thick sections were serially collected and stored in -80 °C.
Immunohistochemistry was conducted according to our previous studies 56, 57 . The information of primary antibodies used for immunohistochemistry in the study were listed in Supplementary   Table 1 . For BrdU immunostaining, sections were pretreated with fresh made 2N HCl (#320331, Sigma) followed by the above immunostaining procedures.
To quantify blood vessel density, we used projected confocal images at 40x magnification (Nikon C1) followed by NIH ImageJ automated processing. At least three sections from each mouse were used for ImageJ quantification. Ten-micron-thick optical sections from 
Western Blot
Protein concentration was assessed by BCA protein assay kit (#23225, Thermo Fisher Scientific). Twenty microgram protein lysates were separated on AnykD Mini-PROTEAN TGX precast gels (#4569035, BIO-RAD) or 10% Mini-PROTEAN TGX precast gels (#4561035, BIO-RAD). The proteins were transferred onto 0.2μm nitrocellulose membrane (#1704158, BIO-RAD) by Trans-blot Turbo Transfer system (#1704150, BIO-RAD). The membranes were blocked with 5% BSA (#9998, Cell signaling) for 1h at room temperature and were incubated overnight with primary antibodies ( Supplementary Table 2 ) at 4 °C. The membranes were washed 3 times with 10 mm Tris-HCl (pH7.5) containing 150 mM NaCl and 0.1% Tween-20 (TBST) and were incubated with horseradish peroxidase-conjugated goat anti-rabbit (31460, RRID: AB_228341, Thermo Fisher Scientific) or anti-mouse (31430, RRID: AB_228307, Thermo Fisher Scientific) for 1h at room temperature. After incubation, the membranes were washed 3 times with TBST. thermocycler. The qPCR primers used in the study were listed in Supplementary Table 3 .
Statistical Analyses
Quantification was performed by blinded observers. All measurements were taken from distinct mice and quantitative data are presented as means ± standard deviation (s.d.). We used scatter dot plots to present the quantification data throughout our manuscript. Each dot (circle, square, or triangle) in the scatter dot plots represents one mouse or one independent experiment. Shapiro-Wilk approach was used for testing data normality. F test was used to compare the equality of variances of two groups whereas Browne-Forsythe test was used for comparing the equality of variances of three or more groups. The statistical methods were described in the figure legends and P value was presented in each graph. For unpaired, twotailed Student's t test, t value and degree of freedom (df) were presented as t (df) in figure legends. Welch's correction was used for Student's t test if the variances of two groups were unequal after Browne-Forsythe test. For comparisons among three or more groups with equal variances (tested by Browne-Forsythe approach), ordinary one-way ANOVA was used followed by Tukey's multiple comparisons, otherwise Welch's ANOVA was used followed by unpaired t test with Welch's correction. In ordinary ANOVA, the F ratio and DFn and DFd was presented as F (DFn, DFd) in the figure legends where DFn stands for degree of freedom numerator and DFd for degree of freedom of denominator. In Welch's ANOVA, the Welch's F ratio, W and DFn and DFd was presented as W (DFn, DFd) in the figure legends. All data plotting and statistical analyses were performed using GraphPad Prism version 8.0. P value less than 0.05 was considered as significant, whereas greater than 0.5 was assigned as not significant (ns).
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Figure Legends
One-way ANOVA followed by Tukey's multiple comparisons, * P < 0.05, ** P < 0.01, *** P < 0.001, ns, not significant. F (2, 9) = 21.73, P = 0.0004 Hk2, F (2, 9) = 14.14, P = 0.0017 Ldha, F (2, 9) = 10.39, P = 0.0046 Pecam1. g-h, representative confocal images of Laminin-positive blood vessels in the spinal cord and the percent of Laminin-positive BV area among total assessed area. One-way ANOVA followed by Tukey's multiple comparisons, * P < 0.05, ns, not significant.
F (2, 11) = 8.8, P = 0.0052. Scale bars = 100 µm. i-j, representative confocal images of Lamininpositive blood vessels in the forebrain cerebral cortex and the percent of Laminin-positive BV area among total assessed area. One-way ANOVA followed by Tukey's multiple comparisons, ** P < 0.01, ns, not significant. F (2, 12) = 16.47, P = 0.0004. Scale bars = 100 µm. k, densities (#/mm 2 ) of ERG + endothelial cells. One-way ANOVA followed by Tukey's multiple comparisons, * P < 0.05, ** P < 0.01, ns, not significant. F (2, 9) = 16.89, P = 0.0009 spinal cord; Welch's ANOVA followed by unpaired t test with Welch's correction, W (2, 5.346) = 65.98, P = 0.0002 cortex.
l, densities (#/mm 2 ) of ERG + /EdU + proliferating endothelial cells (2 hrs EdU pulse labeling prior to tissue harvesting at P8). One-way ANOVA followed by Tukey's multiple comparisons, * P < 0.05, ** P < 0.01, ns, not significant. F (2, 9) = 10.63, P = 0.0043 spinal cord, F (2, 9) = 18.43, P = 0.0007 cortex. group of mice. One-way ANOVA followed by Tukey's multiple comparisons, * P < 0.05, ** P < 0.01, ***, P < 0.001, ns not significant. F (2, 11) = 21.74, P = 0.0002 Vegfa; F (2, 11) = 11.50, P = 0.0020 Ldha; F (2, 11) = 20.31, P = 0.0002 Pecam1. d-e, representative confocal images and quantification of Laminin-positive blood vessels. One-way ANOVA followed by Tukey's multiple comparisons, ** P < 0.01, ***, P < 0.001, ns not significant. F (2, 10) = 105.5, P < 0.0001 cortex; F (2, 13) = 133.2, P < 0.0001 spinal cord. Scale bars = 10 μ m. f-g, densities (#/mm 2 ) of ERG + ECs and ERG + BrdU + proliferating ECs. One-way ANOVA followed by Tukey's multiple comparisons, * P < 0.05, ** P < 0.01, ***, P < 0.001. ERG + ECs, F (2, 10) = 113.1, P < 0.0001 spinal cord, F (2, 12) 2 7 = 169.0, P < 0.0001 cortex; ERG + BrdU + proliferating ECs, F (2, 10) = 24.09, P = 0.0001 spinal cord, F (2, 12) = 86.14, P < 0.0001 cortex. d-e, percentage of Laminin-occupying area among total area at P30. One-way ANOVA followed by Tukey's multiple comparisons, * P < 0.05, *** P < 0.001. F (2, 9) = 332.0, P < 0.0001 spinal cord, F (2, 9) = 59.19, P < 0.0001 cerebral cortex. f, representative confocal images of ERG and IB4 in the spinal cord at P30, scale bars = 20 μ m. g-h, densities (per mm 2 ) of ERG + ECs at P30.
One-way ANOVA followed by Tukey's multiple comparisons, ** P < 0.01, *** P < 0.001. F (2, 10) = 124.1, P < 0.0001 spinal cord, F (2, 9) = 219.2, P < 0.0001 cerebral cortex. a, representative confocal images of Laminin and IB4 in the cerebral cortex of each group of mice at P8 that had been treated with tamoxifen at P1, P2, and P3. b, percentage of Lamininoccupying area among total area at P8. Cortex, one-way ANOVA followed by Tukey's multiple comparisons, * P < 0.05, *** P < 0.001, F (2, 12) = 41.00, P < 0.0001. Spinal cord, Welch's ANOVA followed by unpaired t test with Welch's correction, * P < 0.05, ** P < 0.01 W (2, 6.824) = 11.42, P = 0.0067. c, representative confocal images of Laminin and IB4 in the P8 cerebral cortex of each group of mice that had been treated with tamoxifen at P1, P2, and P3. d, density (#/mm 2 ) of ERG + ECs at P8. One-way ANOVA followed by Tukey's multiple comparisons, ** P < 0.01, *** P < 0.001. F (2, 12) = 92.24, P < 0.0001 cortex, F (2, 12) = 24.37, P < 0.0001 spinal cord.
